FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)																
1. Name and Address of Reporting Person * HEIDEN WILLIAM K				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022										Officer (give	title below)	Oth	er (specify belo	w)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
SOUTH SAN FRANCISCO, CA 94080																		
(City)	(State)	(Zip)			T	able I	- Non-I	Deriv	ative So	ecurities	s Acqui	ired, l	Disposed	of, or Bene	ficially Own	ed	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea		Date, if	(Instr. 8)		(A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5))		Ownership Form:	7. Nature of Indirect Beneficial Ownership
				(IVIOIIII)	Duj	, 1 car)	Cod	e V	A	mount	(A) or (D)	Price			or I	or Indirect	•	
Common	Stock		06/23/2022				A		20 (1),500 1	A	\$ 0	52,0	000			D	
			Table II -					disp uired, D	olays Dispos	s a curi	rently vor Benef	alid O	МВс	ontrol n	unless the umber.	form		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Num	ber vative es ed (A) osed	Expiration Date of Un (Month/Day/Year) Secur		7. Title of Und Securi	Title and Amount 8. Price of		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form of Derivati Security Direct (or Indirects) (s) (I)	Beneficia Ownershi (Instr. 4)			
				Code	v	(A)	(D)	Date Exercis	sable	Expira Date	tion	Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4	
Non- Qualified Stock Option (Right to Buy)	\$ 7.35	06/23/2022		A		31,500)	(2	2)	06/22	2/2032	Comi Sto		31,500	\$ 0	31,500	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
HEIDEN WILLIAM K C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ David Tucker, Attorney-in-Fact	06/27/2022			
Signature of Reporting Person	Date			

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
- (2) The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.